Company profilePharmaceutical#220 of 1,318 in Pakistan✓ No DRAP alerts

Arsons Pharmaceutical Industries (Pvt) Limited

Pharmaceutical company · 81 brands · 72 molecules

Ranked #20 of 207 companies in Quinolone Antibacterials

81 registered products 35 pharmaceutical brands 72 distinct molecules 0 DRAP alerts

Company overview

81
registered products
35
pharmaceutical brands
72
distinct molecules
12
therapeutic classes
0
DRAP alerts

Arsons Pharmaceutical Industries (Pvt) Limited is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 81 product registrations across 72 distinct molecules. Its portfolio is concentrated in Quinolone Antibacterials and Psycholeptics; Antipsychotics, Anxiolytics, Hypnotics And Sedatives. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Arsons

35 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Antifungal For Dermatological 1
Corticosteroid, Plain 1

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

35
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
202535

Top molecules by brand count

Clotrimazole5 brands
Azithromycin3 brands
Linezolid3 brands
Risperidone3 brands
Levofloxacin3 brands
Loperamide2 brands

Therapeutic classes

Quinolone Antibacterials · 6Psycholeptics; Antipsychotics, Anxiolytics, Hypnotics And Sedatives · 4Macrolides, Lincosamides And Streptogramins · 3Antifungal For Dermatological · 2Antiemetics & Antinauseants · 2Agents Against Amoebiasis And Other Protozoal Diseases · 1Anaesthetic, Local · 1Tetracyclines · 1Urologicals, Antiinfectives · 1Antiinflammatory And Antirheumatic Products · 1Beta Blocking Agent · 1Antihaemorrhagic · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official63 products · Rs 52.25 – Rs 3,445
Median across source: Rs 296.72

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

NEUTRO PHARMA (PVT) LTD.33 shared molecules
EPHARM LABORATORIES30 shared molecules
BIO LABS (PVT) LTD.29 shared molecules
IRZA PHARMA (PVT) LTD.28 shared molecules
HIGH - Q INTERNATIONAL26 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

NEUTRO PHARMA (PVT) LTD. holds 109 molecules not in this portfolio
AcetylcysteineAcyclovirAlbendazoleAmikacinAnastrazoleAnastrozole
MEDIATE PHARMACEUTICALS (PVT) LTD holds 94 molecules not in this portfolio
AcyclovirAlendronateAmlodipineAmoxicillinAmpicillinAmpicillin Base
EPHARM LABORATORIES holds 65 molecules not in this portfolio
AlbendazoleAmikacinAmlodipineAnastrozoleAscorbic AcidAtenolol

Get the full profile for Arsons

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.